药物Ⅰ期临床试验中受试者非药物相关三酰甘油、尿酸异常的相关因素

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1003 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the influential factors of non-drug related triglyceride (TG) and uric acid (UA) abnormalities in subjects in phase I clinical trials for drugs.Methods A total of 96 subjects in phase I clinical trial for drugs carried out in Beijing Shijitan Hospital Affiliated to Capital Medical University from February 2021 to February 2022 were selected as the research subjects. The serum TG and UA levels of the subjects were monitored at six time points of D1 (on the day of screening), D3, D5, D15, d43 and d99. The abnormality of TG and UA levels during their participation in the trial and their related factors were analyzed.Results There were 42 cases (43.75%) with abnormal serum TG level and 66 cases (68.75%) with abnormal serum UA level. There were significant differences in the serum TG and UA levels of subjects at each monitoring time point (P<0.05). The serum TG levels of subjects at D3-D99 were higher than those of D1, and the serum UA levels of subjects D5, D43 and D99 were higher than those of D1. The differences were statistically significant (P<0.05). The abnormality of serum TG level of the subjects was correlated with the serum TG level at D1 time point and body mass index (BMI) level (P<0.05), and the abnormality of serum UA level of the subjects was correlated with the serum UA level at D1 time point (P<0.05). The area under receiver operating characteristic curve (AUCROC) of TG at D1 time point and BMI predicting the abnormality of TG was 0.857 and 0.684 (P<0.05), respectively. AUCROC of UA level at D1 time point predicting abnormality of UA was 0.845 (P<0.05).Conclusions In the phase I clinical trial for drugs, the subjects have high proportions of non-drug related TG and UA abnormalities, and their risks are related to baseline TG and UA levels as well as the degree of obesity of the subjects.

Key words： phase I clinical trial non-drug related adverse event triglyceride uric acid related factor

Received: 03 July 2023

ZTFLH:

R969.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LEI Chunpu
	LIU Long
	FAN Rongxia
	WANG Xinghe

Cite this article:

LEI Chunpu,LIU Long,FAN Rongxia等. Analysis of related factors of non-drug related triglyceride and uric acid abnormalities in subjects in phase I clinical trials for drugs[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(2): 116-120.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I2/116

[1]	胡薏慧,严华美,元唯安.提高药物临床试验安全性评价机构管理的建议[J].药物评价研究,2023,46(4):738-742.
[5]	任曼,刘梦晓,李丹,等. 我院药物临床试验65例严重不良事件报告分析[J]. 中国药业,2021, 30(24):18-20.
[6]	Lewis T,Terrin N,Davis J,et al. Inter-rater reliability of the neonatal adverse event severity scale using real-world Neonatal clinical trial data[J]. J Perinatol,2021,41(12):2813-2819.
[2]	刘敏,王海学.药物临床试验不良反应因果关系评价方法概述与存在问题的思考[J].中国临床药理学杂志,2023,39(8):1206-1211.
[7]	Mladsi D,Hess L M,Barnett C L,et al. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study[J]. J Med Econ,2020,23(3):213-220.
[3]	解染,赵侠,张岩,等. 在新药Ⅰ期临床试验中安慰剂引起的三酰甘油变化[J]. 中国临床药理学杂志,2019,35(12):1303-1305.
[8]	曹烨,陈文娜, 吴跃翰,等.新版GCP施行后临床试验机构严重不良事件/可疑非预期严重不良反应报告现状分析与建议[J]. 中国新药杂志,2021,30(10):947-952.
[4]	Zhou Q,Chen X Y,Yang Z M,et al. The changing landscape of clinical trial and approval processes in China[J]. Nat Rev Clin Oncol,2017,14(9):577-583.
[9]	刘婷.20项Ⅰ期临床试验中转氨酶、三酰甘油异常率的回顾性分析[D].长春:吉林大学,2020.
[5]	任曼,刘梦晓,李丹,等. 我院药物临床试验65例严重不良事件报告分析[J]. 中国药业,2021, 30(24):18-20.
[10]	Aghasi M,Koohdani F,Qorbani M,et al. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial[J]. J Sci Food Agric,2019,99(8):3933-3940.
[6]	Lewis T,Terrin N,Davis J,et al. Inter-rater reliability of the neonatal adverse event severity scale using real-world Neonatal clinical trial data[J]. J Perinatol,2021,41(12):2813-2819.
[11]	官政燕, Humayoun A,陈璟,等.社会心理因素与糖、脂、尿酸及肠道菌群代谢紊乱的相互关系[J]. 心理学通讯,2020,3(2):115-120.
[7]	Mladsi D,Hess L M,Barnett C L,et al. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study[J]. J Med Econ,2020,23(3):213-220.
[12]	马伊雯,陈海冰. 心理应激与高尿酸血症的相关性研究进展[J]. 中华风湿病学杂志,2019,23(4):280-283.
[8]	曹烨,陈文娜, 吴跃翰,等.新版GCP施行后临床试验机构严重不良事件/可疑非预期严重不良反应报告现状分析与建议[J]. 中国新药杂志,2021,30(10):947-952.
[13]	Adeyanju O A,Falodun T O,Michael O S,et al. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(6):1055-1066.
[9]	刘婷.20项Ⅰ期临床试验中转氨酶、三酰甘油异常率的回顾性分析[D].长春:吉林大学,2020.
[14]	Katsa M E,Ioannidis A,Sachlas A,et al. The roles of triglyceride/high-density lipoprotein cholesterol ratio and uric acid as predisposing factors for metabolic syndrome in healthy children[J]. Ann Pediatr Endocrinol Metab,2019,24(3):172-179.
[10]	Aghasi M,Koohdani F,Qorbani M,et al. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial[J]. J Sci Food Agric,2019,99(8):3933-3940.
[15]	孙雨诗,李潇,徐静,等. 药物临床试验中肝素钠封管对甘油三酯的影响[J]. 中国临床药理学杂志,2021,37(12):1508-1510.
[11]	官政燕, Humayoun A,陈璟,等.社会心理因素与糖、脂、尿酸及肠道菌群代谢紊乱的相互关系[J]. 心理学通讯,2020,3(2):115-120.
[12]	马伊雯,陈海冰. 心理应激与高尿酸血症的相关性研究进展[J]. 中华风湿病学杂志,2019,23(4):280-283.
[13]	Adeyanju O A,Falodun T O,Michael O S,et al. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe[J]. Naunyn Schmiedebergs Arch Pharmacol,2020,393(6):1055-1066.
[14]	Katsa M E,Ioannidis A,Sachlas A,et al. The roles of triglyceride/high-density lipoprotein cholesterol ratio and uric acid as predisposing factors for metabolic syndrome in healthy children[J]. Ann Pediatr Endocrinol Metab,2019,24(3):172-179.
[15]	孙雨诗,李潇,徐静,等. 药物临床试验中肝素钠封管对甘油三酯的影响[J]. 中国临床药理学杂志,2021,37(12):1508-1510.